Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Hua reports promising phase II results of glucokinase activator HMS-5552

Oct. 17, 2016

Clementia Pharmaceuticals reports positive results from phase II study of palovarotene

Oct. 17, 2016

EMA committee recommends approval of Rekovelle

Oct. 17, 2016

Japan Tobacco and JW Pharmaceutical enter license agreement for JTZ-951 in Republic of Korea

Oct. 17, 2016

Prometic Life Sciences will continue enrollment in phase II trial of PBI-4050

Oct. 13, 2016

Full results from European phase III study of Infacort in pediatric adrenal insufficiency

Oct. 13, 2016

ChemBridge describes GPR131 agonists

Oct. 13, 2016

3SBio announces commercialization license agreement for Byetta and Bydureon in China

Oct. 11, 2016

Abeona Therapeutics' phase I/II study of ABO-102 allowed to proceed

Oct. 10, 2016

Shanghai Yingli Pharmaceutical describes URAT1 inhibitors

Oct. 7, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld
Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Korsana boosts Alzheimer’s work with reverse merger, $380M financing
BioWorld Science
Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...